MedTrace Logo

Mesenchymal Stromal Cells in Kidney Transplant Recipients

NCT02012153 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-06-01

No results posted yet for this study

Summary

The general aim of the present study is to test a cell therapy with autologous ex-vivo expanded mesenchymal stromal cells (MSCs) as a strategy to induce tolerance in living-donor kidney transplant recipients. MSCs will be prepared accordingly to established protocols, starting from bone marrow explants of living-donor kidney transplant recipients obtained 3-4 months before kidney transplant. From these samples, MSCs will be expanded in Good Manufacturing Practice (GMP) approved facilities and used for the present study in patients undergoing kidney transplantation.

Conditions

  • Kidney Transplant Rejection

Interventions

BIOLOGICAL

Mesenchymal Stromal Cells

Sponsors & Collaborators

  • A.O. Ospedale Papa Giovanni XXIII

    collaborator OTHER

  • Mario Negri Institute for Pharmacological Research

    lead OTHER

Principal Investigators

  • Giuseppe Remuzzi, MD · A.O. Ospedale Papa Giovanni XXIII

  • Norberto Perico, MD · Istituto Di Ricerche Farmacologiche Mario Negri

  • Giovanni Rota, MD · A.O. Ospedale Papa Giovanni XXIII

  • Federica Casiraghi · Istituto Di Ricerche Farmacologiche Mario Negri

  • Martino Introna, MD · Laboratorio G. Lanzani, Bergamo, Italy

  • Alessandro Rambaldi, MD · A.O. Ospedale Papa Giovanni XXIII

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-04
Primary Completion
2023-05-29
Completion
2023-05-29

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02012153 on ClinicalTrials.gov